Personalized Medicine's Effect on Oncologists' Treatment Regimens

PERSONALIZED MEDICINE’S EFFECT ON ONCOLOGISTS’ TREATMENT REGIMENSA P R I L , 2 0 1 6

P R E V I E W O F

REPORT OVERVIEW

WHAT YOU WILL LEARN

One aspect of personalized medicine is certain; it is complicated. If you happen to have a highly scientific background, you actually may be able to define the term. However, if you polled five people very familiar with personalized medicine, you should expect to hear five different definitions.

ISR wanted to understand where oncologists stand on the topic of personalized medicine. We interviewed 101 US-based, board-certified oncologists to gather their views on how familiar they are with personalized medicine, how they are treating patients, what tests are being used and which will be used more, and how their patient treatment regimens could evolve in the future.

59 PAGES

101 ONCOLOGISTS

Introduction

SMARTER QUESTIONS SMARTER ANSWERS

MAJOR SECTIONS:1. Current Landscape

2. Genetic Tests and Patient Care

3. Clinical Trial Views

D A T A C O L L E C T I O N I N Q 1 , 2 0 1 6

2 0 - M I N U T E W E B - B A S E D

S U R V E Y

1 0 1 O N C O L O G I S T S F R O M T H E U N I T E D

S T A T E S

• Oncologists’ familiarity with personalized medicine, and perceptions related to hype vs. tangible benefit

• Future predictions for the use and benefits related to personalized medicine in oncology, including potential hurdles to adoption

• Percentage of patients requesting personalized medicine vs. percentage of oncologists suggesting personalized medicine to patients

• Current number of patients treated using genetic tumor profiling vs. oncologists’ predictions for the number in 3 years

• Oncologists’ interest in conducting clinical trials using genetic tumor profiling

• What tests oncologists perform, and how the data are used and stored for use in future clinical trials

F U L L T A B L E O F C O N T E N T S O N N E X T P A G E

http://isrreports.com

Introduction


TABLE OF CONTENTSFOR FULL TABLE OF CONTENTS, PLEASE DOWNLOADTHE FULL PREVIEW AT:

HTTPS://WWW.ISRREPORTS.COM/REPORTS/PERSONALIZED-MEDICINES-EFFECT-ON-ONCOLOGISTS-TREATMENT-REGIMENS/


Introduction


Introduction

INTRODUCTION

4www.ISRreports.com ©2016 Personalized Medicine’s Effect on Oncologists’ Treatment Regimens

INTRODUCTIONWelcome to ISR’s Personalized Medicine’s Effect on Oncologists’ Treatment Regimens report�

If you have been in the pharmaceutical industry for any length of time, it is likely that you have heard of the term “personalized medicine�” If you happen to have a highly scientific background, you actually may be able to define the term� However, if you polled five people very familiar with personalized medicine, you should expect to hear five different definitions�

Personalized medicine got a shot in the arm (maybe a pun) in January 2015 when President Obama from the United States indicated during his State of the Union address that the US would “unveil details about the Precision Medicine Initiative, a bold new research effort to revolutionize how we improve health and treat disease� Launched with a $215 million investment in the President’s 2016 Budget, the Precision Medicine Initiative will pioneer a new model of patient-powered research that promises to accelerate biomedical discoveries and provide clinicians with new tools, knowledge, and therapies to select which treatments will work best for which patients�” Further details on the initiative, including where the money is going and what the goals are, can be found at https://www�whitehouse�gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative�

One aspect of personalized medicine is certain; it is complicated� For example, perhaps the posterchild for personalized medicine is Genentech’s Herceptin� The

Herceptin

HER2Biomarker

Reimbursem

ent

Oncology

Limited Access

Targeted

Precision MedicineInitiativeG

en

etic

following is a description of Herceptin: “Herceptin is a monoclonal antibody that interferes with the HER2/neu receptor� Its main use is to treat certain breast cancers� The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from

S A M P L E P A G E :

INTRODUCTION


Introduction


Introduction

CURRENT LANDSCAPE


Oncologist familiarity with personalized medicineWithout providing a definition of personalized medicine, one-third of US-based oncologists categorize themselves as being “very familiar, I have a complete understanding of the concepts surrounding personalized/precision treatments for oncology patients�”

“How familiar are you with the concept(s) surrounding personalized/precision treatments for oncology patients?” (n=101)

PERSONALIZED MEDICINE’S EFFECT ON ONCOLGISTS’ TREATMENT REGIMENS 14

Oncologist familiarity with personalized medicine Without providing a definition of personalized medicine, one-third of US-based oncologists categorize themselves as being “very familiar, I have a complete understanding of the concepts surrounding personalized/precision treatments for oncology patients.” “How familiar are you with the concept(s) surrounding personalized/precision treatments for oncology patients?”(n=101)

After asking the “familiarity” question to begin the survey, respondents were provided with the following definition: “For the purposes of this research study, we define personalized medicine as the tailoring of medical treatment to the individual characteristics of each patient. The approach relies on scientific breakthroughs in our understanding of how a person's unique molecular and genetic profile makes them susceptible to certain diseases.”

Very familiar, I have a complete

understanding of them32%

Familiar, have a basic understanding

of them44%

I’ve heard of them, but could not define

them17%

Have never heard of them

7%

After asking the “familiarity” question to begin the survey, respondents were provided with the following definition:

“For the purposes of this research study, we define personalized medicine as the tailoring of medical treatment to

the individual characteristics of each patient. The approach relies on scientific breakthroughs in our understanding

of how a person’s unique molecular and genetic profile makes them susceptible to certain diseases.”

© Industry Standard Research


ONCOLOGIST FAMILIARITY WITH PERSONALIZED MEDICINEWithout providing a definition of personalized medicine, one-third of US-based oncologists categorize themselves as being “very familiar, I have a complete understanding of the concepts surrounding personalized/precision treatments for oncology patients.”

C L O S E R L O O K

There are statistical differences in how oncologists from different practice settings (hospital, university, physician-owned) responded to this question.

Learn more in the full report: www.ISRreports.com

PERSONALIZED MEDICINE’S EFFECT ON ONCOLGISTS’ TREATMENT REGIMENS 14

Oncologist familiarity with personalized medicine Without providing a definition of personalized medicine, one-third of US-based oncologists categorize themselves as being “very familiar, I have a complete understanding of the concepts surrounding personalized/precision treatments for oncology patients.” “How familiar are you with the concept(s) surrounding personalized/precision treatments for oncology patients?”(n=101)

After asking the “familiarity” question to begin the survey, respondents were provided with the following definition: “For the purposes of this research study, we define personalized medicine as the tailoring of medical treatment to the individual characteristics of each patient. The approach relies on scientific breakthroughs in our understanding of how a person's unique molecular and genetic profile makes them susceptible to certain diseases.”

Very familiar, I have a complete

understanding of them32%

Familiar, have a basic understanding

of them44%

I’ve heard of them, but could not define

them17%

Have never heard of them

7%


Introduction


Introduction

CURRENT LANDSCAPE


Total (n=101)

Rural (n=11)

C

Suburban (n=40)

D

Urban (n=50)

E

Much more hype than tangible benefit to personalized/ precision oncology treatments today

13% 9% 18% 10%

Somewhat more hype than tangible benefit to personalized/ precision oncology treatments today

35%55%

E45%

E22%

Somewhat more tangible benefit than hype to personalized/ precision oncology treatments today

37% 9% 28%50% C, D

Much more tangible benefit than hype to personalized/ precision oncology treatments today

16% 27% 10% 18%

Statistical differences

Rural oncologists (55%) and suburban oncologists (45%) are more likely than urban oncologists (22%) to indicate “the healthcare industry will view personalized oncology treatments as somewhat more hype than tangible benefit” three years from now�

Urban oncologists (50%) are more likely than rural oncologists (9%) and suburban oncologists (28%) to indicate “the healthcare industry will view personalized oncology treatments as providing a somewhat more tangible benefit than hype” three years from now�

While not tested for statistical significance, urban oncologists seem more likely to view personalized medicine as having more tangible benefit (68%) than rural oncologists (38%) and suburban oncologists (38%)�


STATISTICAL DIFFERENCESThe full data are available in the report, which can be downloaded from www.ISRreports.com.

D A T A I N F U L L R E P O R T


Introduction


FOR ADDITIONAL SAMPLE PAGES, PLEASE DOWNLOAD THE FULL PREVIEW AT:



TO LEARN MORE: CONTACT US AT [email protected] OR +1(919)301-0106

Biosimilars & Biologics

Clinical Trial Recruitment &

Retention

Commercialization Department Models & Structures

Trends & Technologies

Manufacturing Service Provider Quality Benchmarking

CUSTOM RESEARCH

UNDERSTAND YOUR MARKETSLeverage ISR’s experience and institutional knowledge to create a fit-for-purpose market research project that addresses the business decisions you need to make.

Are you:• Developing a new product or service?• Evaluating a new market?• Targeting a new customer segment?• Entering a new geography?• Needing a deeper understanding of your

customer or potential customer base?

UNDERSTAND YOUR CUSTOMERSWho makes the decisions and in what contexts? ISR can help you gain a deeper understanding of your customers’ decision-making units (DMUs) and decision-making processes (DMPs).

Key Questions Addressed:• What motivates the purchase decision?• How are companies, products, solutions, and/or

brands evaluated?• What factors drive the final buying decision?• Where are your customers won or lost in the

purchasing process?• Why were specific opportunities won or lost?• How do you keep customers engaged and

manage their loyalty over time?

CUSTOM RESEARCH SERVICES• Investigator Forum• Brand, Advertising, and Message Testing• Loyalty Management• New Product and Service Development• Competitive Intelligence• Strategy War Games• MORE

S O M E T H I N G T O C O N S I D E R

DISTINCTIVE – Receive novel insights from industry decision-makers on topics including: service provider quality, patient recruitment, biosimilars, clinical technology, manufacturing, clinical operations, and commercial activities.

UNRESTRICTED – ISR doesn’t sell seats. Instantly obtain access for all employees within your organization

AFFORDABLE – Receive access to ALL reports in ISR’s library, as well as those released during your subscription period. ISR’s competitive library pricing equates to the cost of a few individual report purchases.

LIBRARY ACCESS SUBSCRIPTIONISR’s library access subscription provides your entire organization access to our full library of syndicated market research reports (100+ titles) plus access to all reports (~25 per year) released during your subscription period. Our research categories include:

mailto:[email protected]

Introduction


ORDERING INFORMATION

Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise. For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.ISRreports.com, email [email protected], or follow us on twitter @ISRreports.

ABOUT INDUSTRY STANDARD RESEARCH

>> R E G I S T E R N O W>>Receive $250 instant credit towards any ISR report

>>Earn 10% credit towards all future purchases

>>Receive advanced notifications on ISR’s latest reports and free resources

SAVE ON THIS, OR ANY ISR REPORT, BY CREATING A FREE ACCOUNT

FOR PRICING AND ORDERING INFORMATION, PLEASE DOWNLOAD THE FULL PREVIEW AT:



www.ISRreports.com

mailto:[email protected]

https://twitter.com/ISRreports

http://www.isrreports.com/register/

Introduction


www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 10

act with confidenceTHE ISR DIFFERENCE

Mostly primary research; always appropriate for the topic

One size fits all; usually publically available data

To learn more, visit www.ISRreports.com

ISR’S REPORTS

THECOMMON

SYNDICATEDREPORT

VS.

RESEARCH METHODS

ISR’s proprietary data tools and channelssupport fast, high quality data collection

Struggle to recurit the right targets and enough of them

DATA COLLECTION

Sophisticated screening ensures genuine decision-makers make up respondents

Undisclosed methodologies and respondent demographics

RESPONDENTS

Robust sample sizes that instill confidence

Often insucient industry representationthat leaves you defending results

SAMPLE SIZE

Decades of experience means more insights that are immediately usable

Junior analysts capable of reporting numbers

ANALYSTS

ISR’S HEALTH PANELThe industry’s fastest growing panel of health care and pharmaceutical

professionals, with nearly 1,500 members worldwide.

BYJOB

LEVEL

Director 46%

Manager 29%

C-level 13%

VP 10%

BYEXPERIENCE

IN YEARS

16-20 years 23%

11-15 years 24%

6-10 years 11%

3-5 years 5%

20+ years 37%

BYCOMPANY

TYPE

Other 6%

Sponsor 78%

CRO 6%

ResearchSite 10%


www.ISRreports.com

http://www.isrreports.com

Health & Medicine

Personalized Medicine's Effect on Oncologists' Treatment Regimens